key: cord-0750831-00an14nk
authors: Rothenberg, Richard
title: Death and the Virus
date: 2020-05-30
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa679
sha: be5c3ecfe05ce426cdd32968fca9ce126709ba3c
doc_id: 750831
cord_uid: 00an14nk

nan

perspective, what we want to know is a person's probability of dying if infected. From a population perspective, we need to know the groups with the highest risk of death. Some of this is readily apparent: residents of long-term-care facilities [4] , minority persons [5, 6] , obese persons [7] , and people with comorbidities [8] . But a finer-grain understanding of specific CFRs would be a critical tool in targeting interventive approaches.

The article by Deng et al [2] is an object lesson in the importance of specific CFRs and of proper attention to the intimate details of the calculation. Their intimate details start with a meticulous assessment of the validity and accuracy of their 2 datasets, one individual-based and one populationaggregated. They use the raw data, simple description, and a number of manipulative methods (correction factors, curve fitting, regression analysis) to estimate CFR by clinical severity, time-to-event, risk factors, and region. A few simple results illustrate how the CFRs can be used. Half of the cases were aged 45 years and over; half of the deaths were in those aged 75 years and over. The male to female ratio was 60:40. The crude risk ratio between Wuhan, Hubei (the epicenter of the epidemic), and provinces outside Hubei was approximately 10. The CFR among critically ill patients in Wuhan was 86.4%, more than 40 times higher than the CFR in patients with mild disease.

Unfortunately, as interesting and important as these results are, they are not likely to be generalizable. As noted, China and the United States currently have similar CFRs but the relevant factors are substantially different. The therapeutic armamentarium has evolved, and some clinical concerns-coagulopathy [9] , cytokine storm [10] , ventilatory requirements [11] -were not apparent early on. The learning curve has had a palpable effect on the CFR, which underlines the point that a population-averaged CFR has little meaning.

We should laud Deng et al for their efforts to get inside the CFR, and not focus on comparability. The components of composite statistics are often of more value than the overall mean, and only knowledge of those components permits comparison. As with so many epidemiologic parameters, the CFR is a weighted average of subgroups, and knowing the CFRs and proportions of the subgroups permits interventive targeting. In a simple thought experiment, if we hold the age-, sex-, race-specific CFRs constant and simply vary the proportions of each age/sex/race category affected, the overall CFR will obviously change. Targeting older persons and persons of color would lower the prevalence, lower the R 0 , and thereby lower the CFR, and we would be able to say why.

In the months to come, we can expect changes in the critical factors that may work on the CFR in different directions. As our knowledge of the clinical virology improves, and with it better antigen, antibody, and genetic tests, we can expect a much broader understanding of the clinical epidemiology: incubation period and the infectious stages, asymptomatic infectious carriage, and necessary and sufficient contact with humans and surfaces. Prevention measures will evolve that fit a better understanding of the transmission dynamics. In contrast, viral mutation may foster greater virulence [12] . Our great hope-drugs and a vaccine-will be the ultimate determinant of the CFR. 

Case fatality: rate, ratio, or risk?

Case fatality risk of the first pandemic wave of novel coronavirus disease 2019 (COVID-19) in China

COVID-19: coronavirus pandemic

Structural vulnerability in the United States revealed in three waves of novel coronavirus disease (COVID-19)

Characteristics and clinical outcomes of adult patients hospitalized with COVID-19-Georgia

Association of obesity with disease severity among patients with COVID-19

The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients

Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19

A glimpse into the eye of the COVID-19 cytokine storm

Management of respiratory failure due to covid-19

Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2